{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:59:06Z","timestamp":1780786746953,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507000"],"award-info":[{"award-number":["2023YFC2507000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0525700"],"award-info":[{"award-number":["2024ZD0525700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","award":["BMU2024BSS001"],"award-info":[{"award-number":["BMU2024BSS001"]}],"id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242150"],"award-info":[{"award-number":["7242150"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007422097"],"award-info":[{"award-number":["Z221100007422097"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371840"],"award-info":[{"award-number":["82371840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472912"],"award-info":[{"award-number":["82472912"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471866"],"award-info":[{"award-number":["82471866"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271877"],"award-info":[{"award-number":["82271877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jgar.2025.10.011","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:22:50Z","timestamp":1761146570000},"page":"268-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of complicated urinary tract infections or acute pyelonephritis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"45","author":[{"given":"Sirui","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.10.011_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2025.10.011_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOU.0000000000000364","article-title":"An update on classification and management of urosepsis","volume":"27","author":"Wagenlehner","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0004","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of america and the european society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijantimicag.2009.04.012","article-title":"The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections","volume":"34","author":"Schito","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.10.011_bib0006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMcp1503950","article-title":"Urinary tract infections in older men","volume":"374","author":"Schaeffer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.10.011_bib0007","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s42770-021-00624-x","article-title":"Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies","volume":"52","author":"Rather","year":"2021","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0008","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/cid\/cix615","article-title":"The impact of a carbapenem-resistant Enterobacteriaceae outbreak on facilitating development of a national infrastructure for infection control in Israel","volume":"65","author":"Schwaber","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.10.011_bib0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0011","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of Imipenem\/Relebactam vs Colistin plus Imipenem in patients with Imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.10.011_bib0013","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1155\/2005\/385768","article-title":"Complicated urinary tract infection in adults","volume":"16","author":"Nicolle","year":"2005","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0015","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.10.011_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0017","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fphar.2020.00763","article-title":"Effects of Tamsulosin combined with Solifenacin on lower urinary tract symptoms: evidence from a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials","volume":"11","author":"Song","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgar.2025.10.011_bib0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.jgar.2025.10.011_bib0019","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"241","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019"},{"key":"10.1016\/j.jgar.2025.10.011_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jgar.2025.10.011_bib0021","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/sim.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2025.10.011_bib0022","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.10.011_bib0023","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.10.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00236-24","article-title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","volume":"68","author":"Moeck","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/INF.0000000000003832","article-title":"Safety and efficacy of Ceftolozane\/Tazobactam versus Meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: A phase 2, randomized clinical trial","volume":"42","author":"Roilides","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2025.10.011_bib0026","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.10.011_bib0027","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of Ceftazidime-Avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2025.10.011_bib0028","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.10.011_bib0029","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0031","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0032","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.10.011_bib0033","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jgar.2025.10.011_bib0034","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0035","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0037","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0038","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.10.011_bib0039","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.10.011_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/and.14034","article-title":"Association between human papillomavirus infection and sperm quality: a systematic review and a meta-analysis","volume":"53","author":"Wang","year":"2021","journal-title":"Andrologia"},{"key":"10.1016\/j.jgar.2025.10.011_bib0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0042","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12978-023-01684-y","article-title":"Genital mycoplasma infection: a systematic review and meta-analysis","volume":"20","author":"Cheng","year":"2023","journal-title":"Reprod Health"},{"key":"10.1016\/j.jgar.2025.10.011_bib0043","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.011_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of Ceftazidime-Avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical Centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01985-21","article-title":"Antimicrobial activity of ceftazidime-avibactam and comparators against pathogens harboring OXA-48 and AmpC alone or in combination with other \u03b2-lactamases collected from phase 3 clinical trials and an international surveillance program","volume":"66","author":"Lin","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0046","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/antibiotics10111318","article-title":"In-vitro selection of ceftazidime\/avibactam resistance in OXA-48-like-expressing Klebsiella pneumoniae: In-vitro and In-vivo fitness, genetic basis and activities of \u03b2-lactam plus novel \u03b2-lactamase inhibitor or \u03b2-lactam enhancer combinations","volume":"10","author":"Palwe","year":"2021","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.jgar.2025.10.011_bib0047","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1038\/s41598-025-88965-7","article-title":"Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients","volume":"15","author":"Khattab","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2025.10.011_bib0048","first-page":"17","article-title":"Review of in vitro efficacy of ceftazidime-avibactam, meropenem-vaborbactam and imipenem-relebactam in carbapenemase-producing Klebsiella pneumoniae isolates","volume":"12","author":"Aydemir","year":"2023","journal-title":"Mediterr J Infect Microb Antimicrob"},{"key":"10.1016\/j.jgar.2025.10.011_bib0049","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/phar.70036","article-title":"Cefepime-taniborbactam: ushering in the era of metallo-\u03b2-lactamase inhibition","volume":"45","author":"Van Helden","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.10.011_bib0050","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkaf161","article-title":"Aztreonam\/avibactam activity against enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019\u20132023)","volume":"80","author":"Sader","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.011_bib0051","doi-asserted-by":"crossref","first-page":"106633","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.10.011_bib0052","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1038\/s41467-024-52357-8","article-title":"Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii","volume":"15","author":"Baker","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2025.10.011_bib0053","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/ciad010","article-title":"Discordant clinical and microbiological outcomes are associated with late clinical relapse in clinical trials for complicated urinary tract infections","volume":"76","author":"Kadry","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:04:39Z","timestamp":1780783479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S2213716525002292"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of complicated urinary tract infections or acute pyelonephritis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}